Reply to discussion of 'Empirical vs natural weighting in random effects meta-analysis'

Statistics in Medicine

Volumn 29, Issue 12, 2010, Pages 1272-1281

  Shuster, Jonathan J ^a   Hatton, Randy C ^b,c   Hendeles, Leslie ^a,c   Winterstein, Almut G ^b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

DerSimonian Laird; Meta analysis; Phenylephrine; Random effects; Weight

Indexed keywords

PHENYLEPHRINE;

AIRWAY RESISTANCE; AREA UNDER THE CURVE; BINOMIAL DISTRIBUTION; DRUG EFFICACY; EFFECT SIZE; EMPIRICAL RESEARCH; EVIDENCE BASED MEDICINE; MATHEMATICAL MODEL; MATHEMATICAL VARIABLE; META ANALYSIS; METHODOLOGY; NOTE; POLICY; RANDOM SAMPLE; SAMPLE SIZE;

EID: 77952859073     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3842     Document Type: Note

References (21)

1. Laird N, Fitzmaurice G, Xiao D. Comments on 'Empirical vs. natural weighting in random effects meta-analysis'. Statistics in Medicine, DOI: 10.1002/sim.3657.
2. Thompson S, Higgins J. Commentary on 'Empirical vs. natural weighting in random effects meta-analysis' by Jonathan J. Shuster. Statistics in Medicine 2009; DOI: 10.1002/sim.3718.
3. Waksman J. Commentary on 'Empirical vs. natural weighting in random effects meta analysis' by J.J. Shuster. Statistics in Medicine, DOI: 10.1002/sim.3692.
4. Shuster JJ. Empirical vs. natural weighting in random effects meta-analysis by Jonathan J. Shuster. Statistics in Medicine, DOI: 10.1002/sim.3607.
5. Kollar C, Schneider H, Waksman J, Krusinska E. Meta-analysis of the efficacy of a single dose of phenylephrine 10mg compared with placebo in adults with acute nasal congestion due to the common cold. Clinical Therapeutics 2007; 29(6):1057-1070.
6. Waksman J, Kollar C. Comments on 'Rebuttal to Carpenter et al. Comments on 'Fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death' by J.J. Shuster, L.S. Jones, and D.A. Salmon'. Statistics in Medicine 2009; 28(3):534-536.
7. Memo to Wessinger from NA Hulme. Nasal decongestant study by Elizabeth Biochemical No. 2. In FDA OTC volume 040298. January 1968.
8. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. British Medical Journal 1990; 301:309-314.
9. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. The American Journal of Medicine 2008; 121(1):43-49.
10. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley: Chichester, U.K., 2009.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clinical Trials 1986; 7(3):177-188.
12. Emerson JD, Hoaglin DC, Mosteller F. Simple robust procedures for combining risk differences in sets of 2 x 2 tables. Statistics in Medicine 1996; 15:1465-1488. (Pubitemid 26252611)
13. Shuster JJ. Nonparametric optimality of the sample mean and sample variance. American Statistician 1982; 36:176-178.
14. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Yao R, Staudinger H, Danzig MA. Placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Annals of Allergy, Asthma, and Immunology 2009; 102:116-120.
15. Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Annals of Allergy, Asthma, and Immunology 2009; 102:328-338.
16. Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. European Journal of Clinical Pharmacology 1982; 21:335-341.
17. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993; 13:116S-128S.
18. Hatton RC, Winterstein AG, McKelvey P, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Annals of Pharmacotherapy 2007; 41(3):381-390.
19. Memo to Blackmore from NA Hulme. Neo-Synephrine-Elizabeth Biochemical Laboratory Study No. 5. In FDA OTC volume 040298. May 1970.
20. Davey-Smith G, Pakkanen J. Should there be a moratorium on cholesterol lowering drugs? British Medical Journal 1992; 304:431-434.
21. Buyse M, George SL, Evans S, Geller NL, Ranstam J, Scherrer B, Lesaffre E, Murray G, Edler L, Hutton J, Colton T, Lachenbruch P, Verma BL. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Statistics in Medicine 1999; 18(24):3435-3451. (Pubitemid 30041358)